• 1
    Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: Have we made significant progress or is it rime to rethink our analytic and therapeutic strategies? Am J Transplant 2004; 4: 12891295.
  • 2
    Racusen L, Solez K, Colvin R et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713723.
  • 3
    Colvin RB. Chronic Allograft Nephropathy. N Engl J Med 2003; 349: 22882290.
  • 4
    Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002; 346: 580590.
  • 5
    Nankivell B, Richard J, Borrows R et al. The natural history of chronic allograft nephropathy. New Engl J Med 2003; 349: 23262333.
  • 6
    Nankivell BJ, Borrows RJ, Fung C L-S, O'Connell PJ, Allen RD, Chapman JR. Natural history, risk factors, and impact of subclinical rejection in kidney transplantation. Transplantation 2004; 78: 242249.
  • 7
    Kuypers DR. Immunosuppressive drug monitoring—what to use in clinical practice today to improve renal graft outcome. Transpl Int 2005; 18: 140150.
  • 8
    Nankivell BJ, Borrows RJ, Fung C L-S, O'Connell PJ, Chapman JR, Allen RD. Calcineurin-nhibitor nephrotoxicity: Longitudinal assessment by protocol histology. Transplantation 2004; 78: 557565.
  • 9
    Di Paolo S, Teutonico A, Stallone G et al. Cyclosporin exposure correlates with 1 year graft function and histological damage in renal transplanted patients. Nephrol Dial Transplant 2004; 19: 21072112.
  • 10
    Seron D, Moreso F, Fulladosa X, Hueso M, Carrera M, Grinyo JM. Reliability of chronic allograft nephropathy diagnosis in sequential protocol biopsies. Kidney Int 2002; 61: 727733.
  • 11
    Racusen L, Colvin RB, Solez K et al. Antibody-mediated rejection criteria—an addition to the Banff '97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708714.
  • 12
    Racusen LC, Halloran PF, Solez K. Banff 2003 meeting report: New diagnostic insights and standards. Am J Transplant 2004; 4: 15621566.
  • 13
    Moreso F, Serón D, Carrera M et al. Baseline immunosuppression is associated with histological findings in early protocol biopsies. Transplantation 2004; 78: 10641068.
  • 14
    Kuypers DRJ, Claes K, Evenepoel P et al. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: A prospective study in one hundred de novo renal transplant recipients. Clin Pharmacokinet 2004; 43: 741762.
  • 15
    Cockcroft D, Gault M. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 3141.
  • 16
    Hoffmann SC, Kampen RL, Amur S et al. Molecular and immunohistochemical characterization of the onset and resolution of human renal allograft ischemia-reperfusion injury. Transplantation 2002; 74: 916923.
  • 17
    Perico N, Cattaneo D, Sayegh MH, Remuzzi G. Delayed graft function in kidney transplantation. The Lancet 2004; 364: 18141827.
  • 18
    Tullius SG, Reutzel-Selke A, Egermann F et al. Contribution of prolonged ischemia and donor age to chronic renal allograft dysfunction. J Am Soc Nephrol 2000; 11: 13171324.
  • 19
    Nankivell BJ, Fenton-Lee CA, Kuypers DR et al. Effects of histological damage on long-term kidney transplant outcome. Transplantation 2001; 71: 515523.
  • 20
    Shishido S, Asanuma H, Nakai H et al. The impact of repeated subclinical acute rejection on the progression of chronic allograft nephropathy. J Am Soc Nephrol 2003; 14: 10461052.
  • 21
    Nankivell BJ, Chapman JR. The significance of subclinical rejection and the value of protocol biopsies. Am J Transplant 2006; 6: 20062012.
  • 22
    Choi BS, Shin MJ, Shin SJ et al. Clinical significance of an early protocol biopsy in living-donor renal transplantation: Ten-year experience at a single center. Am J Transplant 2005; 5: 13541360.
  • 23
    Cosio FG, Amer H, Grande J, Larson TS, Stegall MD, Griffin MD. Comparison of low versus high tacrolimus levels in kidney transplantation: Assessment of efficacy by protocol biopsies. Transplantation 2007; 83: 411416.
  • 24
    Koziolek MJ, Riess R, Geiger H, Thevenod F, Hauser IA. Expression of multidrug resistance P-glycoprotein in kidney allografts from cyclosporine A-treated patients. Kidney Int 2001; 60: 156166.
  • 25
    Anglicheau D, Pallet N, Rabant M et al. Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine-sirolimus interaction. Kidney Int 2006; 70: 10191025.
  • 26
    Longoni B, Boschi E, Demontis GC, Ratto GM, Mosca F. Apoptosis and adaptive responses to oxidative stress in human endothelial cells exposed to cyclosporin A correlate with BCL-2 expression levels. FASEB J 2001; 15: 731740.
  • 27
    Asai T, Nakatani T, Tamada S et al. Activation of transcription factors AP-1 and NF-kappaB in chronic cyclosporine A nephrotoxicity: Role in beneficial effects of magnesium supplementation. Transplantation 2003; 75: 10401044.
  • 28
    Ekberg H, Grinyo J, Nashan B et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: The CAESAR Study. Am J Transplant 2007; 7: 560570.
  • 29
    Nashan B, Ekberg H, Grinyo J et al. Cyclosporine sparing with the use of mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients—the CAESAR study 36 month results [abstract]. Am J Transplant 2006; 6: 436.
  • 30
    Ekberg H, Tedesco-Silva H, Demirbas A et al. SYMPHONY—comparing standard immunosuppression to low-dose cyclosporine, tacrolimus or sirolimus in combination with MMF, daclizumab and corticosteroids in renal transplantation [abstract]. Am J Transplant 2006; 6: 83.